Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Animal studyNature
Summary
Researchers fed rapamycin, an mTOR pathway inhibitor, to genetically heterogeneous mice starting at 600 days of age and measured survival across three independent test sites. Rapamycin extended median and maximal lifespan in both sexes, with an estimated 14% increase in age at 90% mortality for females and 9% for males. A separate study starting treatment at 270 days also showed improved survival based on an interim analysis near median survival.
Key points
- Rapamycin fed from 600 days of age extended median and maximal lifespan in male and female genetically heterogeneous mice.
- Age at 90% mortality increased by about 14% in females and 9% in males.
- The lifespan effect was reproduced at three independent test sites.
- A separate cohort starting at 270 days showed increased survival in an interim analysis, which is less conclusive than the full study.